89Bio, Inc. Stock Price, News & Analysis

89bio, Inc (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, will have its CEO, Rohan Palekar, participate in investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2, 2020. The conference runs from December 1-3, 2020. An archived webcast of the discussion will be available on 89bio’s website.

89bio is focused on therapies for liver and cardio-metabolic diseases, with its lead candidate, BIO89-100, aimed at treating nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

89bio, Inc. (Nasdaq: ETNB) announced updated positive data from its Phase 1b/2a study of BIO89-100, a treatment for nonalcoholic steatohepatitis (NASH). The study demonstrates significant reductions in liver fat, ALT levels, and triglycerides across various dosing groups with favorable tolerability. Notably, 88% of patients achieved a ≥30% reduction in liver fat. The company plans to initiate a Phase 2b study in early 2021, emphasizing its commitment to addressing NASH's unmet medical needs.

89bio, Inc. (Nasdaq: ETNB) announced significant advancements in its clinical development program during Q3 2020. Positive results from the Phase 1b/2a trial of BIO89-100 for NASH highlighted a 70% liver fat reduction and excellent tolerability. The company is set to present data at the AASLD Liver Meeting and initiate a Phase 2b trial in NASH in H1 2021. Financially, 89bio reported a net loss of $14.6 million, improving from $18.7 million year-over-year, with cash reserves at $219.2 million, supporting ongoing research initiatives.

89bio, Inc. (Nasdaq: ETNB) announced the presentation of promising clinical data for its drug BIO89-100 targeted at treating nonalcoholic steatohepatitis (NASH) during The Liver Meeting Digital Experience™ 2020 from November 13-16. Results from a Phase 1b/2a study revealed significant reductions in liver fat via MRI-PDFF, with favorable safety and tolerability profiles, suggesting potential best-in-class dosing. The study demonstrated robust efficacy with both weekly and biweekly dosing, highlighting the drug's potential as a treatment in a field lacking approved options.

89bio, a clinical-stage biopharmaceutical company focused on liver and cardio-metabolic diseases, announced that CEO Rohan Palekar will present at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020, at 11:30 AM ET. The presentation will be available via live and archived webcast on the company’s website. 89bio's lead product, BIO89-100, targets nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The company is headquartered in San Francisco with operations in Herzliya, Israel.

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced that CEO Rohan Palekar will present at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020, at 11:30 AM ET. The event will be available via live and archived webcast on the company's website. 89bio is focused on developing innovative therapies for liver and cardio-metabolic diseases, with its lead product candidate, BIO89-100, targeting NASH and severe hypertriglyceridemia. The company is based in San Francisco and has operations in Israel.

89bio, Inc. (Nasdaq: ETNB) has announced the pricing of an upsized public offering of 3,300,000 shares at $28.00 each, aiming for gross proceeds of approximately $84.7 million. The offering consists of 3,025,000 shares from 89bio and 275,000 shares from a selling stockholder. Additionally, the underwriters have a 30-day option to purchase up to 495,000 additional shares. The offering is expected to close on September 21, 2020, pending customary conditions. BofA Securities, SVB Leerink, and RBC Capital Markets are leading the offering.

89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), announced a public offering of 3,000,000 shares of common stock. This includes 2,700,000 shares from the company and 300,000 shares from stockholders. There is also an option for underwriters to purchase an additional 450,000 shares. The proceeds will support the BIO89-100 programs targeting nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The offering depends on market conditions and a registration statement that has yet to become effective.

89bio (Nasdaq: ETNB) announced positive topline results from its Phase 1b/2a trial of BIO89-100, an investigational FGF21 analog for nonalcoholic steatohepatitis (NASH). All dose groups achieved significant liver fat reductions, with up to 70% versus placebo. Notably, 88% of subjects had at least a 30% reduction in liver fat. The treatment demonstrated a strong safety profile, with low adverse event incidence. BIO89-100 is positioned as a promising therapy for NASH, with further trials planned in 2021.